Abstract. Glaucocalyxin (Gln), an ent-kaurane diterpenoid isolated from the Chinese traditional medicine, Rabdosia japonica, represents a novel class of anticancer drugs. GlnA is one of the three major forms of Gln and has demonstrated potent anticancer effects in a variety of cancer types. GlnB has only one structural difference from GlnA, an acetylated hydroxyl group at C14. This acetyl group results in high liposolubility and may enhance the antitumor activity of ent-kaurane diterpenoid GlnB. However, few studies have reported the role of GlnB in cancer. The present study investigated the effect of GlnB in cervical cancer proliferation and cell death. Treatment with GlnB inhibits the proliferation of HeLa and SiHa cervical cancer cell lines in a dose-dependent manner, as assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide assays. In addition, GlnB increases the apoptotic cell population of HeLa and SiHa cells, as determined by fluorescence-activated cell sorting analysis and enhanced poly (ADP-ribose) polymerase 1 cleavage by western blotting. GlnB also induces increased light chain 3 II/I protein cleavage in both cells, indicating the induction of autophagy. Furthermore, GlnB treatment increased the expression of phosphatase and tensin homolog and decreased the expression of phosphorylated-protein kinase B (Akt) in HeLa and SiHa cells, as assessed by western blotting. Taken together, the present results demonstrated that GlnB inhibited the proliferation of human cervical cancer cells in vitro through the induction of apoptosis and autophagy, which may be mediated by the phosphatidylinositol-4,5-bisphosphate 3-kinase/Akt signaling pathway.
Introduction
Cervical cancer is the most common malignant tumor in the female reproductive tract. Previously, increased incidence and mortality of cervical cancer, and a younger age at diagnosis were reported, requiring further research and more effective treatment of this deadly disease (1) .
Currently, the combination of radiotherapy with platinum-based chemotherapy is the gold-standard treatment for advanced cervical cancer (2) . Although the addition of platinum-based chemotherapy to radiotherapy has increased the 5-year survival of advanced-stage cervical cancer patients (3) , systemic toxicity limits the use of high-dose chemotherapeutic drugs.
Therefore, alternative therapies for cervical cancer are urgently required. Complementary and alternative medicines can perhaps benefit patients with cervical cancer as an adjunctive therapy. Among them, Chinese traditional medicine has become increasingly prominent and popular in cancer patients due to its efficacy and low toxicity (4) . Glaucocalyxin (Gln), an ent-kaurane diterpenoid isolated from the Chinese traditional medicine, Rabdosia japonica, has been used in traditional medicine as an antibacterial, anti-inflammatory and anticancer agent (5). Gln has three major forms, GlnA, GlnB and GlnC. Previously, GlnA has been intensively studied for its potent anticancer effects and its diverse molecular targets involved in tumorigenesis (6) (7) (8) .
By contrast, few studies have investigated the functions of GlnB. GlnB has only one structural difference from GlnA, an acetylated hydroxyl group at C14. This acetyl group results in high liposolubility and may enhance the antitumor activity of ent-kaurane diterpenoid. The role of GlnB in cancer remains largely unknown. The present study reported that GlnB exerts its anticancer effects by inducing apoptosis and autophagy, and inhibiting proliferation in cervical cancer cells. Chemicals. GlnB, kindly provided by Dr Suping Bai (School of Pharmacy, Xinxiang Medical University, Xinxiang, China) was dissolved in dimethylsulfoxide (DMSO) to make 64 mmol/l stock solutions that was used for all experiments in the present study. Both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and DMSO were purchased from MP Biomedical, LLC (Santa Ana, CA, USA).
Materials and methods

Cell
MTT assay. The cells were incubated overnight at 37˚C in 5% CO 2 in media containing 10% FBS at a concentration of 1,000 cells/well of a 96-well plate. On the next day, the cells were treated with either vehicle control (DMSO) or varying concentrations of GlnB, and were allowed to grow for an additional 72 h. Cell proliferation was assessed using the MTT assay. Following the addition of MTT (20 µl of 5 mg/ml MTT/well), the plate was incubated at 37˚C for 4-5 h. The media was subsequently removed and 150 µl DMSO was added. The plate was then incubated in the same conditions for 5 min. Proliferation was quantified using a plate reader at an optical density (OD) of 570 nm. The cell growth inhibition was calculated as (OD test -OD 0 h ) / (OD control -OD 0 h ) x 10 0%. A cell growth inhibition curve was generated by plotting cell growth inhibition against drug concentration, and the half-maximal inhibitory concentration (IC 50 ) was determined using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA).
A poptosis assay. Apoptosis was a na lyzed using annexin V/propidium iodide (PI) staining, according to the manufacturer's protocol. Briefly, the cells were seeded into 60-mm dishes. On the next day, the cells were treated with either DMSO or varying concentrations of GlnB. After 24 h, the cells were collected by trypsinization, washed twice with cold phosphate-buffered saline and were subsequently resuspended in 1X binding buffer at a concentration of 1x10 6 cells/ml. A total of 100 µl of the solution was transferred to a 5 ml culture tube, followed by the addition of 400 µl 1X binding buffer, and stained with annexin V and PI. The stained cells were immediately analyzed on a FACScan flow cytometer. The stained cells were immediately collected using a BD FACScan flow cytometer (BD, Franklin Lakes, NJ, USA), and data were analyzed using the Winlist program 8.0 (Verity House, Topsham, ME, USA).
Western blotting. Cells grown in the presence or absence of GlnB were lysed in radioimmunoprecipitation buffer. A total of 40 µg total proteins per sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were subsequently blotted onto polyvinylidene difluoride membranes and were blocked for 1 h at room temperature with 5% bovine serum albumen (BSA) in 1X Tris-buffered saline containing 0.1% Tween-20 (TBST). Following blocking, the membranes were probed with anti-PARP1 (1:1,000), anti-LC3 (1:1,000), anti-PTEN (1:500), anti-p-AKT S473 (1:1,000), anti-AKT (1:1,000) or anti-GAPDH (1:1,000) primary antibodies diluted in 5% BSA solution and incubated at 4˚C overnight. The membranes were then washed in TBST and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody (1:1,000; cat. no. 1706515; Bio-Rad, Hercules, CA, USA) for 1 h at room temperature. After washing again in TBST, the membranes were developed using Lumi-Light chemiluminescence substrate (Roche, Indianapolis, IN, USA). Digital imaging and signal quantification were performed on a Chemi-Genius2 Bio-Imager (Syngene, Frederick, MD, USA) using GeneTools software Gene tools 4.01(c) (Syngene).
Statistical analysis. Statistical significances between groups
were determined by two-tailed Student's t-test. P<0.05 was considered to indicate a statistically significant difference. 
A B Results and Discussion
For >40 years, natural products have served us well in combating cancer. Of the antitumor compounds used in medicine, three quarters are natural products or their derivatives, including paclitaxel (9) .
Ent-kaurane diterpenoids, including GlnA, are known to exhibit strong antitumor activities (5). Compared with GlnA, the only structural difference of GlnB is an acetylated hydroxyl group at C14, and this highly liposoluble acetyl group of GlnB makes the compound easier to penetrate into the cells, thereby exhibiting stronger anti-inflammatory properties (10) . The antitumor activity of ent-kaurane diterpenoids is through a similar structure-activity association (5), suggesting that GlnB may have stronger antitumor activity compared with GlnA. Although GlnB has been reported to possess anti-inflammatory activity (10), the role of GlnB in cancer cells remains unclear.
GlnB inhibits cell proliferation in cervical cancer cells in vitro.
To examine whether GlnB affects cervical cancer proliferation, the present study first tested the effect of GlnB on the growth of human HeLa and SiHa cervical cancer cell lines. Following exposure to various concentrations of GlnB for 72 h, cell growth and viability were measured using an MTT assay. GlnB treatment inhibited the growth of HeLa and SiHa cells in a dose-dependent manner (Fig. 1) . The IC 50 of GlnB for HeLa and SiHa cells was 4.61 and 3.11 µmol/l, respectively (Fig. 1) . These data suggested that GlnB treatment inhibited the proliferation of HeLa and SiHa cells. Additionally, the IC 50 determined from in vitro proliferation studies will assist with establishing the doses required for in vivo studies, which will also require the pharmacokinetics data of GlnB and the desired inhibition in vivo. (11) reported that GlnB induces apoptosis in human HL-60 leukemia cells. Apoptosis is a major route to eradicate cancer. Therefore, the present study investigated whether GlnB regulated apoptotic cell death in HeLa and SiHa cells. The cells were treated with varying doses of GlnB for 24 h and apoptosis were assessed using annexin V staining. GlnB treatment increased the population of annexin V/PI-positive cells in a dose-dependent manner in each cell line (Fig. 2A) . The expression of the apoptosis marker PARP1 was examined by western blot analysis. As shown in Fig. 2B , the level of activated and cleaved PARP1 was upregulated in HeLa cells treated with 8 µM GlnB compared with DMSO-treated control cells. Similar results were observed in the SiHa cells treated with 6 µM GlnB (Fig. 2B) . Autophagy is another important mechanism for cancer cell death. Therefore, the effect of GlnB treatment on autophagy was assessed by determining the expression of LC3 II/I by western blot analysis. LC3 I is cleaved to from LC3 II under such conditons. GlnB treatment increased LC3 II/I protein cleavage in both cell lines compared with the DMSO-treated controls (Fig. 2B) . These results indicated that GlnB induces autophagy in cervical cells.
GlnB induces apoptosis and autophagy in HeLa and SiHa cells. Yang et al
Phosphatidylinositol-4, 5-bisphosphate 3-k inase (PI3K)/protein kinase B (Akt) is the central pathway in determining the onset and progression of apoptosis and autophagy (12, 13) . GlnA has been shown to inhibit Akt phosphorylation, suppress proliferation and promote apoptosis in human malignant glioma U87MG cells (7) . Therefore, the present study next examined whether PI3K/Akt signaling is involved in GlnB-induced apoptosis and autophagy. The expression of key signaling proteins involved in this pathway, PTEN, Akt and p-Akt , were assessed by western blot analysis. The results showed that GlnB increased the expression of PTEN and decreased the expression of p-Akt S473 (Fig. 3) . The total Akt remained unchanged by GlnB treatment (Fig. 3) . These findings indicated that the antitumor activity of GlnB is associated with the PI3K/Akt signaling pathway.
In conclusion, the present results demonstrated that GlnB inhibited the proliferation of human cervical cancer cells in vitro via the induction of apoptosis and autophagy, which may be mediated by the PI3K/Akt signaling pathway. Future studies are required to identify the direct molecular target(s) of GlnB and to evaluate its antitumor effects in vivo using animal models. Collectively, the present study demonstrated that GlnB possesses antitumor properties in cervical cancer and may have a therapeutic potential against this deadly disease. Figure 3 . GlnB antitumor activity is involved the PI3K/Akt signaling pathway. HeLa cells were treated with 8 µM GlnB or DMSO for 48 h, and SiHa cells were treated with 6 µM GlnB or DMSO for 24 h. Western blot analysis was performed to determine the expression levels of PTEN, Akt and p-Akt (S473) in HeLa and SiHa cells treated with GlnB. The expression levels were quantified by digitization. GAPDH was used as an internal control. The data shown are representative of two independent experiments. GlnB, glaucocalyxin B; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; Akt, protein kinase B; DMSO, dimethyl sulfoxide; PTEN, phosphatase and tensin homolog; p-, phosphorylated; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
